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Abstract
Background: To document the development and evaluation of the Quality of life Disease Impact Scale (QDIS®), a
measure that standardizes item content and scoring across chronic conditions and provides a summary, norm-
based QOL impact score for each disease.
Methods: A bank of 49 disease impact items was constructed from previously-used descriptions of health impact
to represent ten frequently-measured quality of life (QOL) content areas and operational definitions successfully
utilized in generic QOL surveys. In contrast to health in general, all items were administered with attribution to a
specific disease (osteoarthritis, rheumatoid arthritis, angina, myocardial infarction, congestive heart failure, chronic
kidney disease (CKD), diabetes, asthma, or COPD). Responses from 5418 adults were analyzed as five disease groups:
arthritis, cardiovascular, CKD, diabetes, and respiratory. Unidimensionality, item parameter and scale-level invariance,
reliability, validity and responsiveness to change during 9-month follow-up were evaluated by disease group and
for all groups combined using multi-group confirmatory factor analysis (MGCFA), item response theory (IRT) and
analysis of variance methods. QDIS was normed in an independent chronically ill US population sample (N = 4120).
Results: MGCFA confirmed a 1-factor model, justifying a summary score estimated using equal parameters for each
item across disease groups. In support of standardized IRT-based scoring, correlations were very high between
disease-specific and standardized IRT item slopes (r = 0.88–0.96), thresholds (r = 0.93–0.99) and person-level scores
(r≥ 0.99). Internal consistency, test-retest and person-level IRT reliability were consistently satisfactory across groups.
In support of interpreting QDIS as a disease-specific measure, in comparison with generic measures, QDIS consistently
discriminated markedly better across disease severity levels, correlated higher with other disease-specific measures in
cross-sectional tests, and was more responsive in comparisons of groups with better, same or worse evaluations of
disease-specific outcomes at the 9-month follow-up.
Conclusions: Standardization of content and scoring across diseases was shown to be justified psychometrically
and enabled the first summary measure of disease-specific QOL impact normed in the chronically ill population.
This disease-specific approach substantially improves discriminant validity and responsiveness over generic measures
and provides a basis for better understanding the relative QOL impact of multiple chronic conditions in research and
clinical practice.
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Background
Disease-specific measures of quality of life (QOL) have the
advantage of frequently being more responsive and clinic-
ally useful than generic QOL measures which do not focus
on any specific condition [1–3], while generic measures
have the advantage of enabling comparisons of QOL bur-
den and treatment benefit across diseases [4, 5]. The ad-
vantages of disease-specific measures result in part from
achieving specificity by measuring the frequency and se-
verity of specific symptoms such as joint pain in arthritis
[6] or dyspnea in respiratory disease [7]. Conceptually,
however, such symptoms capture QOL only to the extent
that they are also quantified in terms of their impact on
life or its quality [8].
To achieve the benefits of both measurement traditions,
patient-reported outcome (PRO) surveys have integrated
questions about specific symptoms with disease-specific
and generic QOL measures [9–13]. Content from generic
QOL measures has been incorporated in disease-specific
measures to the point that a primary difference between
them is whether survey questions make attributions to
health in general, a specific component of health (e.g.,
physical or mental), or a specific disease. With more spe-
cific attribution, otherwise generic QOL items have been
shown to differ markedly in their validity and interpret-
ation. For example, a Sickness Impact Profile item [14]
asking about “not accomplishing as much as usual at
work” because of “health”, modified to make attributions
to “physical health” versus “emotional problems”, better
discriminated between physical and mental conditions in
Medical Outcomes Study (MOS) surveys [15, 16]. How-
ever, lack of standardization of QOL content precludes
use of disease-specific measures in making comparisons
across diseases, and substantial gaps in the representation
of QOL content known to be affected by specific diseases
remain [17]. The content areas most often represented in
widely-used generic QOL surveys are not all represented
in any disease-specific survey of which we are aware. One
noteworthy exception, a survey of QOL impact attributed
to headache, comes close to doing so [12].
Disease-specific and generic PROs have a complimentary
relationship. For example, generic measures can monitor
changes in the physical functioning of patients over time in
relation to population norms, regardless of the cause of
any change. Disease-specific measures can help determine
which conditions accounted most for a patient’s limitations
in physical functioning and, therefore, make PROs more
useful in outcomes research, predictive studies of health
care costs, and everyday clinical practice. In theory, trade-
offs between disease-specific and generic measures are un-
necessary. A new approach to measurement is possible, one
that quantifies the impact of each specific condition more
broadly in QOL terms but also allows conditions to be com-
pared on a common metric. This approach uniformly
applies disease attributions to the same QOL content for
every condition and standardizes scoring metrics across
conditions. In other words, one method could achieve the
advantages of both disease-specific and generic PROs. To
the extent that standardized content and scoring across
diseases are justified psychometrically, the new approach
could also compliment generic measures in practice set-
tings, by providing clinicians with a sound basis for com-
paring the relative burden of multiple chronic conditions
in disease-specific QOL terms. Underlying this advance in
methods are some crucial assumptions.
In pursuit of this approach, the Computerized Adaptive
Assessment of Disease Impact (DICAT) project was
launched with NIH support [18, 19]. DICAT’s goals were
to develop a measure of disease-specific impact that was
more comprehensive than existing measures and that
could be standardized to enable comparisons across con-
ditions. This paper documents the development of the
Quality of life Disease Impact Scale (QDIS®), a stan-
dardized disease-specific QOL measure that can be
scored in relation to norms for the chronically ill US
population. It also presents results from initial tests of
psychometric assumptions underlying QDIS construc-




QDIS was developed on the assumptions that disease-
specific attributions can improve the validity of otherwise
generic QOL items enough to interpret them as disease-
specific measures and that the content of disease-specific
measures can be as comprehensive as that of generic mea-
sures. Thus, the 49-item QDIS bank included item content
selected from words and phrases in widely-used generic
and disease-specific surveys, representing ten distinct
health-related QOL domains of physical, role and social
functioning, mobility, emotional distress and well-being,
vitality, sleep, health outlook, cognitive functioning, and
quality of life. A major modification to all QDIS items was
the change in attribution to a specific disease or condition,
as opposed to health in general or no attribution. For ex-
ample, the QDIS item “In the past 4 weeks, how often did
your [CONDITION] limit your physical activities such as
walking or climbing stairs?” (where [CONDITION] was
a specific disease such as angina) was nearly identical to
a generic physical function item previously validated in
the MOS [20] and evaluated, with others, in recent
qualitative studies [21, 22]. A second modification was
to standardize all QDIS content (item stem and re-
sponse categories) across diseases.
To benefit as much as possible from prior work, suc-
cessfully-used descriptions of health impact and oper-
ational definitions were adapted for QDIS. One primary
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source of QDIS content and operational definitions were
full-length generic surveys fielded in the Medical Out-
comes Study (MOS) [16], which included items from
which the 36-item MOS short-form was constructed
[15, 23], and their predecessors as documented else-
where [16, 24–28]. In comparison with the SF-36® Health
Survey, QDIS added content capturing disease impact on
cognitive function, sleep and quality of life. Another source
was item content from seven scales measuring QOL
impact attributed to headache pain [29] and subsequent
adaptations that changed attributions from headache to
other conditions [30–33]. QDIS operational definitions
were matched with item content as much as possible to
improve validity (e.g., behavioral performance or capacity
in measuring physical functioning) and were intentionally
varied to measure multiple aspects of disease impact.
Items were standardized to have the same stem struc-
ture and 5-choice categorical rating scale and a 4-week
recall, the latter to achieve a better time sample of out-
comes. The few exceptions were the global QOL items
and alternate forms of some items included to enable a
cross-walk between alternative methods. In addition to
minimizing local dependence and correlated errors due
to methods effects, this standardization also facilitates
single-item administrations (such as on a PDA) as re-
quired for computerized adaptive administrations. In-
structions, item stems and response categories were
written to be understandable by nearly all US adults.
The 49-item bank has a Flesch-Kincaid Grade Level of
7.3 and a Flesch Reading Ease score of 74.7, which
equates to a reading level of fairly easy [34].
Sampling and data collection
Data came from Internet surveys of the US household
population with oversampling of the chronically ill, fielded
in 2011 in three waves (January-February, July–September,
October–December). The DICAT study was approved by
the New England Institutional Review Board.
Two independent DICAT samples were recruited. The
first (pre-ID) sample, used in item bank development and
evaluation, included panelists aged 18 and older (N = 5418)
who previously reported being diagnosed with any of nine
conditions within five disease groups: arthritis (osteoarth-
ritis, rheumatoid), chronic kidney disease (CKD), cardiovas-
cular disease (angina, myocardial infarction in past year,
congestive heart failure), diabetes, and respiratory disease
(asthma, chronic obstructive pulmonary disease). The sec-
ond sample, used in QDIS norming, was a representative
sample of the U.S. general population age 18 and older,
who had chronic conditions in their naturally-occurring
proportions; data from adults who reported one or more of
35 chronic conditions (N = 4120 out of 5173 total) were an-
alyzed. Panelists in both samples were recruited from the
GfK (formerly Knowledge Networks (KN)) research panel
of approximately 50,000 adults, which uses address-based
sampling from the U.S. Postal Service’s Delivery Sequence
File to represent approximately 97 % of U.S. households.
Unlike convenience (“opt-in”) panels, the KN panel is a
probability-based sample, as recommended for Internet
surveys [35]. It includes cell-phone only households, and
panelists who do not have Internet access are provided
with a computer and Internet connection [36]. Pre-ID
conditions for panelists in the first sample were confirmed
at the start of the DICAT survey, and pre-ID panelists
were sampled to achieve at least 1000 respondents within
three disease groups, with smaller targets for less preva-
lent diagnoses (CKD, cardiovascular).
Panelists were recruited via a routine invitation from KN.
E-mail and IVR telephone reminders were sent to non-
responders. In the pre-ID sample, 9160 panelists received
invitations, of whom 6828 opened the informed consent
screen (consent screening rate of 74.5 %), 5585 consented,
and 5418 completed surveys (survey completion rate of
97.0 %) [37]. Corresponding figures for the general popula-
tion sample were 10,128 invites, 6433 (63.5 %) opened the
informed consent screen, 5332 consented, and 5173 com-
pleted surveys (97.0 %). Responsiveness analyses used Wave
3 data from the pre-ID sample; 2816 Wave 1 pre-ID panel-
ists were invited to complete a Wave 3 survey, of whom
2447 opened the informed consent screen (86.9 %), 2442
consented, and 2384 completed surveys (97.6 %). By design
some Wave 3 respondents did not complete a generic SF-
8™ Health Survey; a total of N = 1889 panelists had QDIS
and SF-8 data in both Waves 1 and 3.
Random assignment to survey protocols enabled admin-
istrations of different survey modules while controlling re-
spondent burden (median total time ≤ 25 min). For pre-ID
and general population samples, the presentation of each
QDIS and other items was identical and modules were ad-
ministered in the following order: generic QOL measures,
35-item chronic condition checklist, 11–49 QDIS items for
one pre-ID condition (pre-ID sample only) and 1–11 QDIS
items for other conditions endorsed, and legacy disease-
specific measures (pre-ID sample only). A total of 4028
pre-ID Wave 1 and Wave 2 panelists completed 49 QDIS
items in the same order for their pre-ID condition, while
1390 randomly chosen pre-ID Wave 2 panelists completed
only 11 QDIS items for their pre-ID condition. All QDIS
administrations began with the same item (everyday activ-
ities or quality of life, see Table 2). Other measures used in
cross-sectional validation and responsiveness comparisons
included the generic SF-8 physical (PCS) and mental
(MCS) component scores, which have been shown to
correlate highly with the SF-36 Health Survey PCS and
MCS [23], along with widely-used disease-specific mea-
sures [6, 7, 11, 38–41] matched to each pre-ID condi-
tion (see Table 6). Internet data collection allowed data
quality to be monitored in real time; accordingly,
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completeness of survey responses was not an issue.
QDIS items had missing data rates of 0.6 to 1.4 %.
Analyses
Evaluation of the 49-item bank included item descriptive
statistics, confirmatory factor analyses (CFA) to test the
psychometric assumptions of unidimensionality underlying
a one-factor model, and multi-group CFA (MGCFA) to
test the equality of factor loadings and thresholds under-
lying the adoption of standardized scoring across diseases.
As recommended [42], psychometric assumptions were
first tested separately in each of the five disease groups and
then for all groups combined. Because satisfying “psycho-
metric” standards of scale construction does not guarantee
improved validity for purposes of measuring disease-
specific outcomes, QDIS and generic measures were com-
pared in cross-sectional and longitudinal tests to evaluate
discriminant validity and responsiveness.
Unidimensionality and item local dependence
Based on prior research [13, 29, 43–45], a 1-factor model
was hypothesized and evaluated for the 49-item QDIS
item bank using CFA with a robust weighted least squares
(WLSMV) estimator and Mplus [46]. To test whether
items were sufficiently unidimensional, the percentage of
variance accounted for by one factor was estimated, and
model fit was evaluated using the following criteria: com-
parative fit index (CFI: >0.95 indicating good fit) and root
Table 1 Characteristics of pre-identified and general population chronically ill samples

















Mean (SD) 62.1 (11.2) 63.5 (12.8) 65.7 (10.7) 60.3 (11.9) 53.0 (16.1) 59.5 (13.7) 50.9 (16.0)
Median 63 64 66 61 55 61 52
Range 20–93 18–92 18–97 18–92 18–93 18–97 18–94
% Male 35.5 51.8 56.6 52.0 35.2 42.8 47.0
Race/Ethnicity
White non-Hispanic 82.5 81.6 84.5 77.6 77.0 79.9 77.3
Black non-Hispanic 6.9 8.0 5.3 11.1 7.3 7.9 8.9
Hispanic 5.3 5.0 2.7 6.2 7.6 5.9 8.4
Other non-Hispanic 5.3 5.4 7.5 5.1 8.1 6.3 5.4
Education
< High school graduate 2.6 4.7 5.6 2.6 3.4 3.3 7.3
High school graduate 20.5 11.7 16.3 19.1 17.8 18.4 26.5
Some college 34.1 41.8 41.9 39.7 38.2 38.0 31.6
College graduate 42.8 41.8 36.2 38.6 40.6 40.3 34.6
Income
< $20,000 11.6 15.1 14.9 10.6 13.7 12.5 13.8
$20,000–39,999 21.6 24.4 26.8 21.9 18.7 21.6 21.4
$40,000–99,999 47.4 44.8 47.4 52.0 48.0 48.6 41.8
$100,000+ 19.4 15.7 10.9 15.5 19.6 17.3 23.0
Employment Status
Employed 35.9 23.7 20.0 43.4 47.0 38.4 52.4
Unemployed 4.0 1.7 2.8 4.8 5.1 4.3 7.0
Retired due to age 38.0 40.5 42.4 33.0 21.1 32.5 19.3
Disableda 12.8 24.4 26.5 10.2 12.3 14.3 7.7
Otherb 8.7 8.7 7.4 7.7 13.9 9.8 13.1
Missing 0.6 1.0 0.9 0.8 0.5 0.7 0.5
Arthritis includes osteoarthritis (N = 1066) and rheumatoid arthritis (N = 508). Cardiovascular includes angina (N = 214), recent myocardial infarction (N = 98), and
congestive heart failure (N = 327). Respiratory includes asthma (N = 1175) and COPD (N = 405)
Abbreviations: CKD chronic kidney disease
aRetired due to disability
bHomemaker, student, other
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mean square error of approximation (RMSEA: <0.06 rec-
ommended, although values are often higher with large
samples [47]). Measurement invariance was evaluated by
testing the fit of nested MGCFA models without (test of
equal forms) and with (test of measurement invariance)
the constraint of equal factor loadings and thresholds
across groups, using the DIFFTEST option in Mplus [46]
and the percentage change in CFI [48]. Plots of disease-
specific and standardized (across groups) factor loadings
and thresholds also were inspected. Noteworthy residuals
(r > 0.20, absolute value) were flagged to identify any not-
able shared item variance not accounted for by the 1-
factor model which might indicate item local dependence,
as in previous analyses [49].
Differential item functioning
Ordinal logistic regression (OLR) methods [50] were
employed to test for uniform and non-uniform differential
item functioning (DIF) for groups differing in age (<65, 65
+) and gender, using the R software package lordif [51].
Meaningful DIF was identified by a change in Nagelkerke's
R2 (for uniform plus non-uniform DIF) >0.03 [52] or a
proportionate change >5 % in the beta coefficients (β1) for
the trait measured (disease impact) in OLR models with
and without the group variable [53].
Item Response Theory (IRT) modeling
IRT parameters were estimated independently for each
group (disease-specific parameters) and the combined
sample (standardized parameters) using a Generalized
Partial Credit Model (GPCM) [54] as in previous studies
[17, 55–57] and Xcalibre™ 4 software [58]. Goodness-of-
fit was evaluated using chi-square item fit statistics [59] ac-
knowledging that IRT models for polytomous items may
misfit even when violations are very small [60]. To evaluate
item-level invariance across independent groups, scatter-
plots for item slopes and thresholds were compared for 10
unique pairs of five disease groups using ResidPlots [61]. In
addition, because insufficient item-level invariance may be
without practical consequences [60] or may be offset by
opposite effects [17], scale-level scores estimated using
disease-specific and standardized item parameters were
evaluated in each group using product–moment correla-
tions and graphical scatterplots as in a parallel study [17].
Item bank reduction and short form development
A 25-item bank was developed from the 49-item bank for
use in CAT administrations when the cost of item transla-
tions and of recording items for oral administrations are
important considerations. Selection of items for the shorter
bank and a 7-item short form (QDIS-7) was based on the
following criteria (ordered in terms of priority): (a) com-
prehensive representation of content areas; (b) steep item
slope; (c) incremental validity in predicting total bank theta
score; (d) utilization in real-data CAT simulations of the
49-item bank [62]; (e) item information functions indica-
tive of reliability over a wide range of theta values, and (f)
item fit statistics. Content representation without redun-
dancy was a priority. When multiple items represented the
same content area and achieved nearly equal discrimin-
ation (slope) and incremental validity in predicting theta,
higher rates of CAT utilization and higher item informa-
tion over a wider range determined choices between them.
As illustrated in Results, lack of fit in terms of traditional
fit statistics was ignored in favor of item usefulness (dis-
crimination, CAT utilization).
The 7-item static (QDIS-7) and adaptive 6-item CAT
(QDIS-CAT-6) short forms were both scored using stan-
dardized IRT parameters and norm-based algorithms (see
below). Because these forms were very highly correlated
at baseline (r = 0.97–0.98 across five disease groups)
and yielded virtually identical results in cross-sectional
tests of discriminant validity, results are reported for
QDIS-7. Baseline results for QDIS-CAT-6 are reported
in Additional file 1: Table S1 and Additional file 2:
Table S2.
Reliability
IRT estimates of the precision of scores at the person-
level were compared across severity levels (none/mild,
moderate, severe/very severe). At the group-level, in-
ternal consistency reliability (Cronbach’s alpha (1951)
[63]) and test-retest reliability were estimated. Test-
retest reliability was estimated using intraclass correl-
ation coefficients (ICC) in a sample of Wave 2 panelists
including approximately equal numbers from each dis-
ease group and severity level, who completed a second
QDIS survey within two weeks.
Validity
To test the hypothesis that changing item attributions
from health in general to a specific disease improves
the validity of QDIS as a disease-specific measure, one-
way analyses of variance (ANOVA) compared scores
for QDIS and generic SF-8 measures across identical
groups reporting different severity levels within each
disease. For the combined pre-ID groups, sample sizes
were sufficient for ANOVAs across all five severity
levels. The ratio of F-ratios [64] was used to calculate
relative validity (RV) and differences in RV were tested
for significance as documented elsewhere [65]. We hy-
pothesized that QDIS-7 would discriminate across dis-
ease severity groups better than generic measures. In
addition, product–moment correlations were estimated
to test the hypothesis that correlations with legacy
disease-specific QOL measures would be higher for
QDIS than for generic SF-8 measures.
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Responsiveness
To extend initial tests to include responsiveness, analysis
of variance (ANOVA) compared self-evaluated transition
(SET) groups in terms of change scores (9-month follow-
up minus baseline) for QDIS and generic SF-8 measures.
SET groups were formed from responses (much better,
somewhat better, about the same, somewhat worse, much
worse) to the question “Compared to 9 months ago, how
much better or worse is your < DISEASE > now?”, where
DISEASE was the pre-ID condition. Because simulation
studies showed that more reliable scores were most useful
for the more severely chronically ill, Wave 3 QDIS scores
were estimated from a single-item (QL1) supplemented by
a 1–9 item CAT only for those with severe QOL impact
(QL1 score of “a lot” or “extremely”) [66]. QDIS scores es-
timated using this method had a high correlation (r = 0.90)
with the static QDIS-7 and nearly identical means (50.03
vs 49.97, respectively, for QDIS-7 and adaptive CAT) in
evaluations of Wave 1 data. ANOVA F-statistics for Wave
3 SET groups were compared using RV estimates as
above [65]. Because groups were defined based on eval-
uations of change in the pre-ID condition, we hypothe-
sized that QDIS-7 would be more responsive than
generic SF-8 measures. Results are reported here for all
conditions combined.
Norm-based T-score transformation
IRT-calibrated QDIS scores were transformed to have a
mean of 50 and standard deviation (SD) of 10 using a linear
T-score transformation of scores for all US general popula-
tion sample respondents reporting any chronic condition
(N = 4120). A higher score indicates greater disease impact
(worse health). Independent observations, one per person,
were weighted using KN-derived sampling weights to
adjust the sample to the demographic distribution of the
December 2010 Current Population Survey [67]. Norm-
based estimates of central tendency, variability and percent-
ile ranks for QDIS-7 were examined. For the combined
pre-ID groups, sample sizes were sufficient to estimate
norms for each of five severity levels.
Results
Sample characteristics
Characteristics of the pre-identified disease samples
and chronically ill norming sample are summarized in
Table 1. Except for the respiratory group, pre-ID sam-
ples tended to be older than the normative sample. The
latter sample was also more likely than the pre-ID sam-
ples to be employed, but was less highly educated on
average. Other characteristics were similar. The charac-
teristics of the subset of pre-ID respondents followed
longitudinally did not materially differ from those doc-
umented in Table 1.
Item descriptive statistics
Table 2 summarizes item wording, content classifications,
sample sizes, item-level descriptive statistics and other re-
sults (discussed below) for the combined pre-ID sample. N
for most items differed only slightly (N = 3995–4044);
exceptions included the global quality of life (QL1) and
10 other items randomly administered more often (N =
5372–5399). Underlying consistently low means were
large proportions (39–82 %, median = 60 %) endorsing
the lowest impact response category.
Unidimensionality and item local dependence
In support of a generalizable 1-factor model, one domin-
ant factor explaining 80–86 % (median = 84 %) of the total
variance was observed across the five disease groups. Item
factor loadings were consistently very high in the com-
bined sample (0.81–0.96; median = 0.92) and each dis-
ease group (Table 3). The CFI was satisfactory in all
five disease groups (0.979–0.991) and combined sample
(0.982), and the RMSEA was acceptable (0.058–0.077
across diseases; 0.074 in combined sample). Fit of the
equal form (χ2(5635) = 20,023.4, CFI = 0.987, RMSEA =
0.064 (90 % CI 0.063,0.065)) and measurement invari-
ance (χ2(6411) = 20,927.7, CFI = 0.987, RMSEA = 0.060
(0.059,0.061)) multi-group CFA models was satisfac-
tory. While the Mplus DIFFTEST for the two models
was significant (χ2diff (776) = 2583.5, p < 0.0001), it is
known to be sensitive to sample size [48] and the CFI
did not differ (to the nearest thousandth) between the
two models. Further, examination of modification indices
did not support respecification of the model. Accordingly,
the 1-factor solution was accepted across disease groups.
Almost no evidence of item local dependence was ob-
served among 1176 residual correlations in each of the
five groups and combined sample (total of 7056 residuals);
only one residual correlation (HO2/HO36, r = 0.202) in
one disease (CKD) exceeded 0.20. Thus, no items were
eliminated from the 49-item bank.
Differential item functioning
There was no noteworthy DIF by age or gender. The
median change in Nagelkerke’s R2 was ≤0.001 across
items for both age and gender and the highest ΔR2 was
0.006, well below the threshold ΔR2 of 0.03. Similarly,
the median percentage increase in β1 was <0.3 % for
both age and gender and the maximum increase was
3.3 %, below the threshold of 5 %.
IRT and other item-level properties
Table 2 summarizes IRT and other item-level properties
for all 49 items, including IRT slopes and factor loadings,
which are directly related [42]. It identifies (**) seven
items chosen for QDIS-7 with the following abbreviated
item content (content area designation in parentheses):
Ware et al. Health and Quality of Life Outcomes  (2016) 14:84 Page 6 of 16
Table 2 Item content and statistics, 49-item disease-specific QOL impact bank
Ordera Areab Abbreviated Contentc N Mean (SD) rd ae b Rangee Fitf Imax at Θg CATh
1** QL Everyday activity, QOLi 5399 1.80 (1.04) .956 3.55 0.18–2.11 191.9 6.26 (1.20) 100
44 QL Activity enjoyment lifei 4044 1.79 (1.03) .946 2.63 0.20–2.28 151.0 4.20 (1.10) 0
2** HO Worry health future 5372 2.11 (1.13) .844 1.49 −0.10–1.86 371.9 1.90 (1.35) 42
36* HO Concern worry 4022 1.90 (1.08) .868 1.84 0.13–1.97 284.2 2.65 (1.55) 28
10** PF Usual physical activities 4019 1.96 (1.12) .920 3.10 0.00–1.93 158.2 4.76 (1.45) 55
3* PF Physical activity walking 5386 1.95 (1.20) .876 2.20 0.25–1.64 148.5 4.11 (1.15) 0
47* MB Stay inside house 4008 1.57 (1.04) .894 2.41 0.87–1.94 132.5 5.60 (1.20) 0
27** RL Work daily activities 4015 1.87 (1.09) .964 5.30 0.08–1.89 114.4 9.67 (1.40) 64
5* RL Everyday activities 5381 1.77 (1.06) .957 4.67 0.26–1.96 101.6 8.64 (1.50) 41
15* RL Get done work home 4026 1.91 (1.14) .940 3.88 0.11–1.83 123.6 6.97 (1.50) 14
17* RL Cancel work activity 4015 1.42 (0.85) .921 3.47 0.88–2.17 71.9 7.46 (1.95) 2
23* RL Limited usual activities 4006 1.77 (1.04) .948 4.50 0.20–1.97 89.2 8.70 (1.65) 14
26* RL Accomplished less 5395 1.97 (1.16) .937 3.88 0.07–1.78 85.9 6.94 (1.40) 28
30* RL Leisure activities 4017 1.35 (0.75) .873 2.47 1.05–2.49 152.9 4.35 (2.15) <1
33* RL Productive work other 4012 1.54 (1.00) .945 4.12 0.72–1.96 44.9 9.81 (1.00) 26
49* RL Daily work in and out 3995 1.84 (1.09) .954 4.52 0.14–1.88 101.5 8.73 (1.60) 34
8 RL Daily tasks help 4020 1.72 (1.06) .856 1.93 0.55–1.94 183.1 3.37 (1.35) 0
13 RL Usual daily activitiesj 4020 1.73 (1.01) .941 4.14 0.25–2.14 107.0 7.12 (1.30) 0
19 RL Stop work other activity 4012 1.75 (1.02) .911 3.09 0.27–2.05 89.1 5.38 (1.75) 0
35 RL Simple tasks hard 4006 1.81 (1.08) .923 3.58 0.22–1.93 104.6 6.48 (1.60) 0
38 RL Keep from traveling 4017 1.46 (0.97) .916 2.42 1.11–1.95 177.0 6.32 (1.30) 0
41 RL Restrict recreational 4014 1.48 (0.90) .897 2.64 0.87–2.17 122.5 5.04 (1.20) 0
42 RL Cut down amount time 4011 1.68 (1.04) .942 3.97 0.43–1.97 72.7 7.73 (1.70) <1
6** SA Social family friends 5383 1.56 (0.96) .950 4.56 0.57–2.04 107.1 9.69 (1.75) 30
37* SA Enjoying social activities 4007 1.60 (0.98) .945 4.34 0.52–2.08 93.3 8.29 (1.65) 19
45* SA Hard to get along with 4006 1.52 (0.87) .853 2.05 0.75–2.43 208.3 3.26 (1.65) <1
9 SA Enjoyment family friends 4020 1.63 (0.98) .915 3.05 0.50–2.19 93.0 5.16 (0.90) 0
14 SA Avoid social activities 5399 1.55 (0.97) .938 3.59 0.68–2.12 67.9 7.52 (1.00) 0
21 SA Uncomfortable people 4015 1.43 (0.85) .890 2.57 0.93–2.09 135.7 5.54 (1.85) 0
32 SA Travel take trip 4012 1.52 (1.02) .915 2.48 0.98–1.82 75.8 6.53 (1.30) 0
40 SA Family social leisurek 4015 1.40 (0.80) .920 3.33 0.92–2.60 81.8 6.73 (1.10) 1
4** FT Worn out, tired 5384 1.94 (1.13) .923 3.41 0.06–1.81 96.5 6.17 (1.45) 19
28* FT Bed most of day 4018 1.30 (0.73) .878 2.37 1.34–2.42 124.8 5.23 (1.60) <1
18 FT Need lie down rest 4012 1.92 (1.12) .884 2.44 0.16–1.92 124.9 3.71 (0.55) 0
46 FT Too tired to workj 4007 1.70 (0.98) .932 4.01 0.26–2.22 107.4 6.70 (1.35) <1
20* SL Good night sleep 5387 1.94 (1.14) .810 1.52 0.31–1.86 294.0 2.27 (1.15) 26
11** EM Frustrated fed up 4011 2.03 (1.21) .871 1.99 0.14–1.74 209.3 3.12 (0.70) 36
7* EM Bothered emotionally 5378 1.67 (1.00) .906 2.04 0.53–2.00 117.4 3.71 (1.60) 0
16* EM Interest enjoyment 4018 1.81 (1.07) .940 4.26 0.20–2.01 110.6 7.19 (0.60) 17
22 EM Losing control life 4006 1.56 (0.97) .898 2.35 0.78–1.99 89.0 4.40 (1.70) 0
24 EM Tense feel anxious 4007 1.67 (0.99) .895 2.37 0.46–2.07 107.1 4.07 (1.70) 0
29 EM Fed up frustratedj 4032 1.68 (0.99) .895 2.39 0.39–2.14 167.8 4.29 (1.45) 0
31 EM Letting others down 4019 1.58 (1.03) .914 2.86 0.78–1.89 64.1 6.42 (1.05) 0
34 EM Angry act irritable 4001 1.63 (0.98) .885 2.09 0.61–2.03 111.8 3.71 (1.65) 0
Ware et al. Health and Quality of Life Outcomes  (2016) 14:84 Page 7 of 16
everyday activities or quality of life (QL), worry about
health in future (HO), limited in usual physical activities
(PF), difficulty in work or daily activities (RL), limited in
usual social activities with family, friends or others (SA),
worn out or tired (FT), and frustrated or fed up (EM).
Table 2 also identifies 25 items recommended for use in
CAT administrations.
Item thresholds were most often positive due to skew-
ness and were consistently ordinal for each item (data not
reported). Item slopes and CAT utilization agreed consid-
erably, while item fit and CAT utilization tended to dis-
agree; for example, only one of 10 best fitting items was in
the top 10 in CAT utilization and five of the latter were
among the 10 worst fitting items. The first item in Table 2,
QL1, was selected as the first item for QDIS-7 and CAT
administrations based on face validity (“everyday activity”
and “quality of life” content), a wide range of thresholds,
one of the least skewed response distributions, and a very
high CFA loading, even though it had a lower slope than
many items. Items chosen for QDIS-7 generally included
the best item from each of the seven represented content
areas in regressions testing incremental validity in relation
to the total bank theta score. One exception was the
QDIS-7 role functioning item, which was the second best
predictor from that content area but was selected because
it had much higher CAT utilization. If based entirely on
Table 2 Item content and statistics, 49-item disease-specific QOL impact bank (Continued)
39 EM Feel desperate 4009 1.38 (0.82) .904 2.43 1.08–2.25 114.5 5.25 (1.60) 0
43 EM Depressed sad 5388 1.62 (0.99) .911 2.04 0.71–1.98 134.1 3.84 (1.50) 0
25* CG Difficult to focus 4009 1.53 (0.89) .921 3.38 0.60–2.20 91.7 6.63 (1.95) <1
12 CG Focus on work 4010 1.74 (1.02) .927 3.68 0.29–2.09 51.6 6.24 (1.70) 0
48 CG Ability to concentratej 4004 1.51 (0.86) .923 3.66 0.60–2.36 69.3 6.48 (2.05) 3
aOriginal order of administration in 49-item bank. *In 25-item bank. **In 25-item bank and 7-item short-form
bContent area: QL = quality of life, HO = health outlook, PF = physical functioning, MB =mobility, RL = role functioning, SA = social activity, FT = fatigue, SL = sleep,
EM = emotional, CG = cognitive
cAll items used 5-choice (Never-Very often) categorical rating scale except: i5-choice (Not at all-Extremely) scale; jCross-calibration item used 5-choice (None-All of
the time) and (Never-Very often) scales in different waves; kItem used 5-choice (Never-Always) scale
dCorrelation with factor in 1-factor confirmatory factor analysis, all diseases combined (N = 3152)
eSlope (a) and range of thresholds (b) in IRT model, all diseases combined
fS-X2 fit statistic, values above 118.75 are significant at a .05 level
gImax at Θ is maximum of the item information function (first number) at a particular theta (number in parentheses)
hPercentage of times item utilized in 6-item real-data CAT simulation using 49-item bank. Item QL1 was the start item for the CAT
Table 3 Summary of item-level CFA and IRT evaluations by disease group and all diseases combined and disease-specific versus
standardized inter-scale correlationsa
Disease Confirmatory Factor Analysis IRT parameters Item r with
theta scored
Inter-scale
correlationseΧ2 df CFI RMSEA (90 % CI) Factor Loadingsb Residualsc Slopes Thresholds
Arthritis 7037 1127 0.979 0.077 0.91 0.026 2.58 0.99 0.76 0.9996
(0.076–0.079) 0.74–0.94 0.00–0.143 1.18–4.02 −0.83–2.72 0.59–0.86
CKD 1865 1127 0.991 0.058 0.93 0.026 3.55 1.36 0.76 0.9983
(0.053–0.062) 0.76–0.97 0.00–0.202 1.29–5.94 −0.24–2.38 0.62–0.83
Cardiovascular 3658 1127 0.987 0.069 0.92 0.022 3.13 1.18 0.75 0.9998
(0.067–0.072) 0.81–0.96 0.00–0.141 1.62–5.51 −0.20–2.71 0.59–0.86
Diabetes 3991 1127 0.985 0.061 0.91 0.027 2.98 1.85 0.70 0.9992
(0.059–0.063) 0.81–0.97 0.00–0.186 1.36–6.05 −0.29–2.99 0.51–0.81
Respiratory 4847 1127 0.990 0.060 0.92 0.021 3.13 1.50 0.75 0.9999
(0.058–0.061) 0.84–0.97 0.00–0.124 1.64–5.87 0.10–2.67 0.58–0.86
Combined 20,669 1127 0.982 0.074 0.92 0.023 3.05 1.34 0.74 -
(0.073,0.075) 0.81–0.96 0.00–0.158 1.49–5.30 −0.10–2.60 0.58–0.85
Abbreviations: Χ2 chi-square test of model fit, df degrees of freedom, CFI comparative fit index, RMSEA root mean square error of approximation, CKD chronic
kidney disease
aAll entries are median on first line and minimum-maximum on second line unless noted
bLoadings from the completely standardized CFA solution for each disease (rows 1–5) or all diseases combined (row 6)
cAbsolute value of residual correlations after controlling for single factor for each disease (rows 1–5) or all diseases combined (row 6)
dCorrelation between person-level item scores and total bank theta scores for each disease (rows 1–5) or all diseases combined (row 6)
eCorrelation between person-level total bank theta scores estimated using disease-specific and standardized item parameters
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item-level fit (“Fit” in Table 2), most QDIS-7 items would
not have been chosen for that static short-form. It is note-
worthy that “misfitting” (by traditional standards) items
often had very high factor loadings, were among the best
predictors of the theta score, and were among the items
most often utilized by CAT.
Medians and ranges of disease-specific and standard-
ized (combined) QDIS item slopes were very similar and
highly correlated (r = 0.88–0.96) as were threshold pa-
rameters (r = 0.93–0.99) across disease groups (Table 3,
Additional file 3: Figure S1 and Additional file 4: Figure S2).
This pattern was confirmed across all 10 pairs of slopes (r
= 0.79–0.89) and thresholds (r= 0.90–0.98) estimated inde-
pendently for the five disease groups (Additional file 5:
Table S3). Median item-theta score correlations were very
high (r = 0.70–0.76 across disease groups), and their ranges
also were similar across groups (Table 3). As shown in the
plots in Additional file 3: Figure S1 and Additional file 4:
Figure S2, estimates of thresholds were more robust than
slopes across standardized and disease-specific estimates
but both demonstrated substantial linearity.
Person-level scale scores
Scale-level (theta) scores estimated using standardized
and disease-specific item parameters were very highly
correlated (r > 0.99) (Table 3) and showed near perfect
linearity in plots for each of the five groups (Additional
file 6: Figure S3). These results support the notion that
any differences between disease-specific and standard-
ized item parameters affecting scale-level scores in one
direction were offset by differences in other items in the
opposite direction.
Reliability
Internal consistency reliability was consistently high for
QDIS-7 scores (alpha = 0.91–0.94) across diseases (Table 4).
The percentages of person-level IRT reliability estimates
exceeding 0.90 were very high (72–100 %, median = 93 %)
for the moderate and severe groups, for whom precision is
most important clinically, but lower (34–60 %) for none/
mild groups. For the 376 panelists completing QDIS-7 re-
test surveys within 5–14 days (median = 8 days) and
reporting their health was the same, test-retest reliability
was satisfactory (ICC = 0.83–0.91 across groups).
Validity
In cross-sectional tests of validity in discriminating across
severity levels, QDIS means increased progressively with
greater disease severity in all five diseases (Table 5). In
support of the hypothesis that disease-specific QDIS mea-
sures were more valid than generic measures, a signifi-
cantly (p < 0.05) higher F-ratio for mean differences across
severity levels was observed for QDIS-7 (RV= 1.0) in com-
parison with SF-8 physical and mental measures (RV =
0.05–0.65, median = 0.18) in every disease group. Increases
in both mean severity level separations and reductions in
within group variances for QDIS-7 contributed to these re-
sults. The orders of magnitude of F-statistics for QDIS were
markedly larger (1.5 to 20 times, median = 5.6 times) than
those observed for generic measures in the same com-
parisons. In tests of convergent validity, correlations be-
tween QDIS-7 scores and corresponding legacy QOL
measures for the same disease were very high (r = 0.71–
0.83) (Table 6). A similar pattern of moderate to high
correlations (r = 0.54–0.74, median = 0.66) was observed
between QDIS-7 and corresponding disease severity
Table 4 Comparison of QDIS-7 means and reliability estimates, five disease groups
Disease Mean (SD)a % with IRT Reliability ≥0.90 by Severity Levelb Alphac Test-retest
reliabilitydMild Moderate Severe Total
Arthritis 54.24 (8.72) (N = 718) (N = 587) (N = 231) (N = 1536) .94 .88
60.5 93.5 95.7 78.4
CKD 48.97 (9.17) (N = 200) (N = 61) (N = 36) (N = 297) .94 .91
34.5 82.0 94.4 51.5
Cardiovascular 51.65 (9.87) (N = 483) (N = 112) (N = 36) (N = 631) .94 .90
55.5 95.5 91.7 64.7
Diabetes 47.60 (7.75) (N = 921) (N = 329) (N = 63) (N = 1313) .91 .83
38.6 72.0 100.0 49.9
Respiratory 48.45 (9.45) (N = 1152) (N = 306) (N = 112) (N = 1570) .94 .88
36.4 87.3 93.8 50.4
Abbreviations: CKD chronic kidney disease
aAnalysis of variance indicated that QDIS-7 group means differed across disease groups (F(4,5413) = 152.1, p < 0.0001). QDIS-7 scores have mean = 50, SD = 10 in
chronically-ill US general population; higher scores equal worse health
bPercent with IRT estimated reliability ≥0.90. Severity defined as Mild (None, Mild), Moderate, or Severe (Severe, Very Severe) in response to item How would you
rate the severity of your < condition > in the past 4 weeks?
cInternal consistency reliability for arthritis (N = 1113), CKD (N = 261), cardiovascular (N = 578), diabetes (N = 857) and respiratory groups (N = 1156)
dIntraclass correlation coefficient (ICC(3,1)) for arthritis (N = 109), CKD (N = 37), cardiovascular (N = 63), diabetes (N = 75) and respiratory groups (N = 92)
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ratings within all five disease groups. QDIS-7 consist-
ently had higher correlations with other disease-specific
measures than with generic physical (r = −0.43 to −0.69,
median = −0.52) and mental (r = −0.38 to −0.51, me-
dian = −0.44) summary measures.
Responsiveness
In longitudinal analyses, 59.4 % reported the same pre-
ID disease status at 9-month follow-up and those who
changed were more likely better (24.6 %) than worse
(16.0 %). Table 7 compares mean changes in QDIS and
physical and mental scores across five groups reporting
different disease-specific outcomes. In support of the hy-
pothesis that disease-specific QDIS measures are more re-
sponsive than generic measures, Table 7 shows a much
higher F-ratio (F = 29.8, p < 0.0001) for QDIS-7 (RV = 1.0)
in comparison with generic physical (F = 14.2, p < 0.0001)
and mental (F = 2.1, NS) measures, and significantly lower
RV estimates (RV = 0.47 and 0.07, respectively). This pat-
tern of results, which supports QDIS responsiveness as a
disease-specific measure, was replicated across pre-ID
groups analyzed separately with one exception (equivalent
QDIS and generic SF-8 PCS RV estimates for OA).
Norms
Norm-based descriptive statistics for five disease-specific
severity levels for the combined pre-ID sample are docu-
mented in Additional file 7: Figure S4 for use in interpret-
ing cross-sectional results. QDIS means and medians
differed substantially and were ordered as hypothesized
across severity levels. A noteworthy floor effect was ob-
served only in the least severe (None) group.
Discussion
QDIS combines the strengths of two traditions within
QOL measurement. It harnesses the precision and dis-
criminability of disease-specific assessment with the com-
prehensiveness of generic QOL assessment. The result is
an approach that differs from available disease-specific
measures in noteworthy ways. First, and foremost, it
Table 5 Comparison of relative validity (RV) of QDIS-7 and generic measures in discriminating across severity levels, five disease groups
Disease/
Measure
Mean (SD) by Self-Evaluated Severitya F-ratio RVb 95 % CIc
Mild Moderate Severe
Arthritis (N = 688) (N = 564) (N = 214)
QDIS-7d 49.2 (6.88) 57.4 (5.83) 64.9 (5.81) 586.27 1.00
SF-8 PCSe 48.1 (7.60) 40.9 (8.65) 31.2 (8.22) 383.73 0.65 (0.56,0.76)
SF-8 MCSe 51.8 (8.08) 48.8 (10.19) 44.7 (11.40) 49.19 0.08 (0.05,0.12)
CKD (N = 189) (N = 56) (N = 33)
QDIS-7 44.7 (6.96) 53.3 (7.72) 61.3 (8.40) 87.99 1.00
SF-8 PCS 42.2 (11.10) 37.3 (10.61) 33.3 (7.50) 12.41 0.14 (0.06,0.26)
SF-8 MCS 50.4 (9.43) 45.6 (11.82) 44.4 (11.33) 8.15 0.09 (0.02,0.20)
Cardiovascular (n = 469) (n = 107) (n = 35)
QDIS-7 48.5 (8.83) 58.9 (6.66) 65.6 (5.60) 123.29 1.00
SF-8 PCS 41.8 (10.25) 34.2 (8.55) 30.4 (7.21) 43.32 0.35 (0.24,0.50)
SF-8 MCS 49.8 (9.70) 46.5 (10.70) 39.1 (12.74) 21.47 0.17 (0.07,0.30)
Diabetes (N = 870) (N = 317) (N = 58)
QDIS-7 45.3 (6.42) 51.5 (7.21) 59.0 (5.85) 196.01 1.00
SF-8 PCS 48.4 (8.76) 44.4 (9.93) 40.6 (11.03) 36.59 0.19 (0.11,0.28)
SF-8 MCS 51.9 (8.08) 48.4 (9.75) 42.6 (11.49) 44.33 0.23 (0.13,0.34)
Respiratory (N = 1106) (N = 297) (N = 109)
QDIS-7 44.7 (7.10) 56.4 (6.71) 64.3 (7.07) 622.23 1.00
SF-8 PCS 48.1 (9.46) 41.4 (10.20) 33.4 (10.84) 149.30 0.24 (0.18,0.30)
SF-8 MCS 49.5 (9.34) 46.4 (11.65) 42.2 (12.06) 32.74 0.05 (0.03,0.08)
Abbreviations: CKD chronic kidney disease
aSeverity defined as Mild (None, Mild), Moderate, or Severe (Severe, Very Severe) in response to item How would you rate the severity of your < condition > in the
past 4 weeks?
bRelative validity (RV) is computed as the ratio of the comparator F-statistic over the QDIS-7 F-statistic
cComparator confidence intervals (CI) estimated using bootstrap
dQDIS-7 scored so a higher score equals worse health
eNorm-based scoring of SF-8 Health Survey summary measures based on a representative probability sample of the US general household population surveyed in
2011, norms (mean = 50, SD = 10) scored so a higher score equals better health
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standardizes both content and scoring across diseases,
which to our knowledge has never been done before.
Second, disease-specific QOL impact content represen-
tation has been increased to be on a par with that of
comprehensive generic QOL measures. Third, in sup-
port of interpreting QDIS as a disease-specific measure,
results from this initial evaluation showed that QDIS dis-
criminated across disease severity levels and responded
when groups differed in disease-specific outcomes at
9 months markedly better than generic measures. Fourth,
QDIS is the first disease-specific measure standardized
across diseases and normed in a representative sample of
the chronically ill general population.
Standardization began with the content of the same 49
items, differing only in disease-specific attribution. Scoring
of a single summary measure was based upon formal tests
that confirmed a unidimensional model, consistent with
previously-reported results for other disease-specific sum-
mary measures [13, 29, 43–45]. Further, the equivalence of
parameters across disease groups was sufficient to justify
their standardization, and very high (r > 0.99) agreement
was observed between disease-specific and standardized
IRT-based score estimates. Subsequently, an independent
test of standardized versus study-specific QDIS-7 item
parameters estimated for acute coronary syndrome
(ACS) patients showed sufficient IRT invariance to war-
rant use of standardized parameters in studies compar-
ing QOL impact for ACS and other conditions [17]. In
addition to very high (r = 0.99) scale-level agreement
between ACS-specific and standardized score estimates,
this replication is noteworthy because ACS data were
collected by telephone interviews versus Internet-based,
self-administrations in DICAT.
What is the importance of leveraging broader generic
QOL content for purposes of measuring disease-specific
impact? By definition, content validity is greater with
more complete representation of relevant content areas
[3, 8, 68, 69]. Furthermore, representing multiple content
areas in QDIS probably results in a more interesting sur-
vey administration, in contrast to answering items about
the same content multiple times [70]. Respondents also
may identify more with one QOL impact description than
another. If so, multiple distinct descriptions may be more
likely to capture disease impact and expand the usefulness
of information available for interpreting research results
and for clinicians and patients to discuss.
Like all measures relying on disease-specific attribu-
tions, QDIS assumes that respondents with multiple
Table 6 Correlations of QDIS-7 with disease-specific and generic measures, five disease groups
Disease N Disease-specific severitya Disease-specific QOLb Generic Physicalc Generic Mentalc
Arthritis 925 0.72 0.71 −0.69 −0.44
CKD 240 0.66 0.83 −0.44 −0.43
Cardiovascular 542 0.65 0.72, 0.79 −0.52 −0.51
Diabetes 695 0.54 0.72, 0.72 −0.43 −0.49
Respiratory 848 0.74 0.83 −0.58 −0.38
QDIS-7 scored so a higher score equals worse health
Abbreviations: CKD chronic kidney disease
aSelf-rating of disease severity (5 categories, None-Very Severe)
bDisease-specific QOL measures are Arthritis: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC®) Total scale [6]; CKD: Kidney-Disease
Quality of Life 36-item instrument (KDQOL-36™) Burden scale [11]; Cardiovascular: Angina/MI-Seattle Angina Questionnaire Quality of Life scale [38] (first entry
N = 275) and CHF-Minnesota Living with Heart Failure® Questionnaire total scale [39] (second entry, N = 267); Diabetes: Problem Areas in Diabetes Scale total scale
[41] (first entry) and Diabetes Quality of Life measure total scale [40] (second entry); Respiratory: St. George’s Respiratory Questionnaire total scale [7]. All disease-
specific measures are scored so a higher score equals worse health
cSF-8 Health Survey physical and mental component summary measures scored so a higher score equals better health
Table 7 Responsiveness of QDIS-7 and generic measures in comparisons across groups differing in self-evaluated outcomes during
9-month follow-up, all diseases combined
Measure Mean change score by self-evaluated outcomea F-ratio RVb 95 % CIc
Much better Somewhat better Same Somewhat worse Much worse
(N = 244) (N = 245) (N = 1181) (N = 282) (N = 37)
QDIS-7d −2.76 −0.04 1.29 3.20 5.87 29.80 1.00 -
SF-8 PCSd 1.36 −0.71 −0.28 −3.22 −4.98 14.15 0.47 (0.24,0.85)
SF-8 MCSd 1.33 −0.47 0.14 −0.33 −0.91 2.06 0.07 (0.00,0.15)
aSelf-evaluated change groups were defined as much better, somewhat better, about the same, somewhat worse, or much worse now in response to the
question: “Compared to nine months ago, how much better or worse is your < DISEASE > now?”, where DISEASE was the pre-ID condition
bRelative validity (RV) is computed as the ratio of the comparator F-statistic over the largest F-statistic for that comparison
cComparator confidence intervals (CI) estimated using bootstrap
dNorm-based scoring of all measures based on US general population norms (mean = 50, SD = 10). QDIS-7 scored so a higher score equals worse health; SF-8
scored so a higher score equals better health
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chronic conditions (MCC) can validly differentiate the
specific impact of one disease from that of others, a
rarely tested assumption. Although our initial results
comparing measures differing in attributions to a spe-
cific disease versus health in general support this as-
sumption, current study methods did not test it directly.
For example, the greater validity and responsiveness ob-
served for QDIS over generic measures could reflect the
impact of a comorbid condition. This crucial issue has
been addressed in a parallel study [71] of adults with
MCC. Results from multitrait-multimethod (MTMM)
tests of construct validity [72] based on analysis of DICAT
data for 4480 respondents with MCC strongly support the
assumption that adults can validly differentiate the specific
impact of one condition from that of others. Briefly, re-
sults from MTMM tests of up to 26 comorbid conditions
within each of eight pre-ID conditions demonstrated con-
vergent validity; correlations among three methods (QDIS,
severity, symptoms) of measuring the same condition were
substantial (r = 0.38 to 0.84, median = 0.53) across pre-ID
conditions. In contrast, as hypothesized for discriminating
measures, correlations between methods of measuring dif-
ferent conditions were significantly lower than correspond-
ing convergent correlations in 833 of 924 (90.2 %) tests;
exceptions were most often observed for comorbid condi-
tions in the same clinical area. It follows from these results
and those reported in this paper that the standardized
QDIS approach based on attributions to specific diseases
warrants further tests of its use in quantifying and com-
paring each disease as well as aggregating scores to esti-
mate the cumulative burden of multiple diseases, thereby
addressing an important measurement gap [69].
Historically, an advantage of generic QOL measures over
disease-specific measures has been the availability of gen-
eral population norms for use in interpreting generic out-
comes. However, this tradeoff is unnecessary to the extent
that disease-specific populations can be defined and sam-
pled. A practical limitation to widespread standardization
and norming has been the many different disease-specific
measures. By standardizing both content and scoring, QDIS
enables a practical approach to the norm-based interpret-
ation of disease-specific QOL impact throughout the
chronically ill population. To make norm-based interpret-
ation easier, scores were transformed to have a mean of 50
and SD of 10 in the US chronically ill household popu-
lation using a T-score transformation, such as that
adopted for the SF-36 [73], SF-12® [74] and SF-8 [23]
Health Surveys and PROMIS® [75]. By placing all
disease-specific scores on the same QOL impact metric,
clinicians can better understand the implications of dif-
ferences in disease severity with a level of specificity
that is not possible with a generic measure and re-
searchers can aggregate patient scores for predictive
and outcome analyses across diseases.
Modeling issues
Considerable art is involved in the application of measure-
ment theory and methods to the measurement of QOL
impact. Accordingly, different interpretation of the mul-
tiple criteria applied here or the application of different
methods might have led to different selections of items for
the 7-item static form (QDIS-7) and the 25-item bank. In
our Methods and Results sections, we have attempted to
explain the logic that was applied in considering item-
specific evidence of many types. To facilitate other choices
and replications in other disease groups, we have docu-
mented results for the entire 49-item bank.
The strong support for a 1-factor model observed in
every disease group studied is consistent with previous
findings for QOL items making attributions to specific con-
ditions [13, 29, 43]. It is also in sharp contrast to measure-
ment models for generic items and scales that confirm
conceptually- and empirically-distinct subdomains and
higher-order physical and mental factors [73, 76]. In
marked contrast, it appears that adults asked to focus
on a specific condition make QOL attributions more
on the basis of differences in the overall severity and
QOL impact of each condition and less on the basis of
the different aspects of QOL (e.g., physical, emotional,
role/social).
QDIS scored using the classical method of summated rat-
ings [77] and IRT item parameter estimates correlated very
highly throughout the score range in every disease group.
Hence, scores estimated using both methods can be trans-
formed (mean = 50, SD = 10) throughout the chronically ill
US population. However, well-documented and noteworthy
advantages of IRT models, such as more accurate CAT-
based estimates of individual scores at every level of theta,
would be lost in the absence of IRT-based item parameters.
Alternate forms
Because electronic data capture is not always possible, the
QDIS-7 fixed-length form was evaluated in parallel with
CAT as in previous studies [57, 62, 65]. In support of the
direct comparability of norm-based scoring of both ap-
proaches, the correlation between the static QDIS-7 and
QDIS-CAT-6 scores ranged from 0.97 to 0.98 across the
five disease groups studied and mean estimates were
nearly identical across measures. We also extended the
adaptive logic at the 9-month follow-up by using CAT
only for those patients suspected of scoring in the most
impaired range and relying on a noisier but unbiased
single-item QDIS estimate (QL1) for those showing lower
or no impact. The gains in efficiency included a nearly
80 % reduction in respondent burden while still achieving
the hypothesized superiority in responsiveness over gen-
eric outcome measures. This alternative to static short-
form and routine fixed-length CAT measurement warrants
further study, particularly for purposes of individual-level
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applications requiring greater reliability than group-level
comparisons.
The single-item QDIS estimate (QL1) correlated 0.89
with the 49-item bank theta score and produces unbiased
(although coarse) estimates of disease-group means across
population surveys and large-group studies if scored using
the recommended T-score transformation. This single-
item measure has also been shown to achieve convergent
and discriminant validity among adults with multiple
chronic conditions (MCC). Therefore, it may provide a
practical pathway to a standard global QOL impact meas-
ure that uses disease-specific attribution to measure total
MCC impact. Such an aggregate measure may be a valid
addition to the toolkit for adjusting for differences in case
mix in observational studies of patient-reported outcomes.
Limitations
Although replications across diseases are rare for new ap-
proaches to QOL measurement, it is a limitation that only
nine conditions in five disease groups were the basis of ini-
tial QDIS development and validation. The consistency of
results across diseases suggests that the findings are likely
to generalize to other physical conditions. Analyses of sub-
groups—OA and RA within arthritis, asthma and COPD
within respiratory, and angina, MI and CHF within cardio-
vascular—replicated findings reported here, although with
some limitations due to smaller samples. However, all of
the pre-ID disease groups were physical health conditions,
and the omission of any pre-ID mental health groups is a
noteworthy limitation of the current study. Self-reported
depression, not analyzed here, was prevalent (13–26 %)
across the pre-ID groups and was shown elsewhere to be
validly measured by QDIS as a comorbid condition [71].
We recommend extension of future studies to include
mental and other physical diseases.
Another potential limitation is reliance entirely on self-
reports for disease severity and legacy disease-specific
measures. Although self-report methods have been useful
in validation [16, 75] results may have been different if
“criteria” had been based on independent clinical evalua-
tions. Although any self-report bias is unlikely to account
for the superior discriminant validity observed for QDIS
over generic measures, QDIS should be evaluated in re-
lation to more objective clinical criteria, which are also
likely to make interpretation guidelines more useful
clinically. Examples of more independent clinical valid-
ation include a recent trial using QDIS with attribution
to smoking; QDIS correlated substantially higher with
four biomarkers of smoking exposure [78] and discrim-
inated between current and former smokers much bet-
ter [79] than generic SF-36v2® Health Survey measures.
Similarly, QDIS with attribution to kidney disease dis-
criminated across clinically-defined stages of CKD bet-
ter than the SF-12 [65].
The lack of new patient involvement in selecting and
modifying QDIS items is a noteworthy potential limitation
of the current study. Although QDIS item selection and
modification benefited from previous qualitative studies of
phrases in the QDIS items, it is possible that de novo
qualitative studies would lead to further improvements, if
changes in attributions from health to a specific condition
materially change item meaning or clarity. To what extent
does changing the attribution of QOL impact from health
in general to a specific disease require additional patient
involvement in qualitative evaluation [80]? The advantage
of more such evidence is the opportunity to add findings
from qualitative studies to the rich array of evidence in
Table 2 and to better understand the inevitable trade-
offs in choosing among items. However, single-disease
studies often ignore the presence of multiple chronic
conditions. Accordingly, we recommend that qualitative
research be conducted systematically among patients
with MCC for QDIS and other measures that use
disease-specific attributions.
Recommendations for future research
In addition to the issues noted above, the psychometric
properties of items selected for administration in static
QDIS short forms or by CAT warrant further study. Our
observation that some of the poorest fitting items in
terms of traditional fit statistics were the most predictive
and most utilized by CAT led us to consider multiple
criteria in selecting items for QDIS-7 and the 25-item
bank, including information functions at the most preva-
lent score levels. Further, more in-depth tests of item-
and scale-level parameter invariance analogous to the
ACS study [17] are likely to be informative.
To the extent that current study findings are
generalizable to other conditions for which comprehen-
sive disease-specific QOL measures are not readily avail-
able, QDIS may enable a substantial short-cut to achieving
disease-specific QOL impact estimates. Examples include
applications to rare diseases and the evaluations of orphan
drugs. Patient and clinician input in establishing clear and
familiar terminology for disease-specific attribution would
be a prerequisite and assumptions underlying scoring, reli-
ability and validity would need to be evaluated, as always
should be done for a new disease application of a stan-
dardized measure. However, for conditions lacking a sum-
mary QOL impact measure, QDIS may be a practical
solution that does not require years of development and
considerable resources.
Conclusions
Overall, this pursuit of disease-specific QOL measure-
ment innovation appears to be on the right track toward
filling the conceptual and methodological gaps between
disease-specific symptoms that do not measure quality
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of life and generic QOL measures that do not measure
disease-specific outcomes. By integrating the richness of
generic QOL item content with disease-specific attribu-
tions and by standardizing scoring metrics, QDIS
achieves some of the advantages of both disease-specific
and generic PRO measurement traditions. The result is a
new method for comparing outcomes across diseases
while retaining the advantages of disease-specific mea-
sures. The broader representation of item content in
QDIS may expand knowledge about the various ways in
which specific diseases impact patients’ quality of life
and the benefits of their treatment. To facilitate its use,
information about QDIS and permission to use it for
scholarly and commercial applications is available at
www.jwrginc.com.
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